Sublingual Aspirin

Sublingual Aspirin, which addresses cardiology emergencies and pain management, is a powder formulation of 112 mg of fast-acting aspirin, and has been developed by using our patent-pending formulation, and “trade secret” process.

Benefits of “rapid absorption” aspirin are: to stop heart attack and stroke; allow high dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.

Sublingual Aspirin Product is also targeted to be a safe and effective Opioid alternative.

Aspire’s Launch Product: Sublingual, Rapid-Absorbing Aspirin

In the initial launch of its sublingual drug application, Aspire has focused on the delivery of aspirin, which may be the most studied and accepted analgesic and anti-inflammatory. Aspirin is over a century old and is traditionally available in several forms, effervescence, powder and tablet. Over 100 years of documented safety and efficacy data is readily available. Aspirin is the only drug in history to receive a certified recommendation by the FDA for heart attack, stroke and colon cancer. However, current aspirin applications are limited due to side effects such as irritation to gastric membranes.

Sublingual Aspirin Product has limited side effects, nor is it metabolized through the liver.

We further expect that our sublingual aspirin product will be well positioned to target the current Opioid Crisis globally due to its ability to have large doses rapidly be absorbed in the bloodstream with no harmful effects to the gastric system and its mucous membrane, as well as, at full strength with no dilution due to metabolic impact, providing true anti-inflammatory therapeutic effects to users and providing true pain management relief to them.

Initially, Aspire intends to commercialize its novel soluble formulation for aspirin for cardiology and stroke emergencies and pain management. Aspire’s technology utilizes a new mechanism of action which allows for rapid sublingual and high absorption in the mouth. This sublingual delivery method avoids direct damage to mucus-secreting goblet cells lining the gastrointestinal tract as well as avoiding bioavailability reduction by first-pass hepatic metabolism as seen through alternative delivery methods such as suppository, intramuscular and transdermal.

Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a powder formulation of a fast-acting aspirin, which has been developed by using our patent-pending formulation, and “trade secret” process.

In the Company’s launch product, the 112 mg aspirin formulation, this is critical in stopping heart attacks and strokes, and the high-dosage formulation is effective for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.

Aspire hopes to target the analgesics market and plans to launch its first sublingual aspirin product for the prescription market in 2026. The Company also sees an opportunity to generate licensing revenues in FY2025 by licensing its proprietary technology to third-party pharmaceutical companies for other drugs. Aspire has also launched its rapid absorbing caffeine supplement Buzz Bond™ in August 2025.